StockData
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. (KAPA) stock

KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.40−0.01 (-1.70%)

Close on Nov 17, 2026Market cap $1.49MP/E –Yield –

Kairos Pharma cash

Cash and short-term investments held at the end of each period.

Kairos Pharma's cash was $3.13M at Sep 30, 2026. For fiscal 2025 it was $4.49M, up 253.1% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.49M+253.1%
FY2024Dec 31, 2024$1.27M+1267.7%
FY2023Dec 31, 2023$93.00K-78.7%
FY2022Dec 31, 2022$437.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$3.13M-43.9%
Q2 FY2026Jun 30, 2026$2.63M-13.4%
Q1 FY2026Mar 31, 2026$3.68M+1.6%
Q4 FY2025Dec 31, 2025$4.49M+253.1%
Q3 FY2025Sep 30, 2025$5.58M+73.3%
Q2 FY2025Jun 30, 2025$3.03M+14347.6%
Q1 FY2025Mar 31, 2025$3.62M+8940.0%
Q4 FY2024Dec 31, 2024$1.27M+1267.7%
Q3 FY2024Sep 30, 2024$3.22M+3149.5%
Q2 FY2024Jun 30, 2024$21.00K-95.2%
Q1 FY2024Mar 31, 2024$40.00K–
Q4 FY2023Dec 31, 2023$93.00K–
Q3 FY2023Sep 30, 2023$99.00K–
Q4 FY2022Dec 31, 2022$437.00K–

More Kairos Pharma figures

See a number that looks wrong?